NASDAQ:INNT

Innovate Biopharmaceuticals Stock Forecast, Price & News

$1.32

0.00 (0.00 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.23

Now: $1.32▼

$1.34

50-Day Range

$0.56

MA: $0.94▼

$1.42

52-Week Range

$0.37

Now: $1.32▼

$1.67

Volume4.22 million shs

Average Volume525,982 shs

Market Capitalization$54.55 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.39

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

MarketRank^™

Overall MarketRank^™

0.48 out of 5 stars

Medical Sector

1383rd out of 1,558 stocks

Pharmaceutical Preparations Industry

596th out of 638 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Innovate Biopharmaceuticals.

2.4 Community Rank

Outperform Votes
Innovate Biopharmaceuticals has received 203 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Innovate Biopharmaceuticals has received 214 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Innovate Biopharmaceuticals has received 51.32% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote “Outperform” if you believe INNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Innovate Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Innovate Biopharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innovate Biopharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Innovate Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 5.88% of the stock of Innovate Biopharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Innovate Biopharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innovate Biopharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:INNT

Previous Symbol

CUSIPN/A

CIK1551986

Webwww.innovatebiopharma.com

Phone919-275-1933

Employees8

Debt

Debt-to-Equity RatioN/A

Current Ratio0.35

Quick Ratio0.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.27) per share

Price / Book-4.89

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-27,050,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-234.42%

Miscellaneous

Outstanding Shares41,325,000

Market Cap$54.55 million

Next Earnings DateN/A

OptionableOptionable

$1.32

0.00 (0.00 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INNT stock has increased by 180.0% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Innovate Biopharmaceuticals?

Wall Street analysts have given Innovate Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Innovate Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11).
View Innovate Biopharmaceuticals' earnings history.

Who are some of Innovate Biopharmaceuticals' key competitors?

Some companies that are related to Innovate Biopharmaceuticals include Oncternal Therapeutics (ONCT), Sol-Gel Technologies (SLGL), Harrow Health (HROW), Eton Pharmaceuticals (ETON), Milestone Pharmaceuticals (MIST), NuCana (NCNA), Sernova (SEOVF), Cerecor (CERC), Assembly Biosciences (ASMB), Exicure (XCUR), Medicenna Therapeutics (MDNA), Sesen Bio (SESN), Theratechnologies (THTX), Theratechnologies (THERF) and Tonix Pharmaceuticals (TNXP).
View all of INNT's competitors.

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), (CGC), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and Aurora Cannabis (ACB).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:

Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
Dr. Christopher P. Prior, Consultant (Age 66)
Jerry Gardner M.D., Head of Clinical Strategy
Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $1.32.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $54.55 million. Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here